Delta-8-THC association with psychosis: A case report with literature review

Abstract

BackgroundCannabis (Δ9-THC) is the most commonly consumed illicit drug. The Agricultural Improvement Act of 2018 removed hemp, a strain of Cannabis sativa, as a controlled substance. This law allowed the plant to be processed into its components, which contain <0.3% Δ9-THC. As a result, delta-8-tetrahydrocannabinol (Δ8-THC), a federally unregulated substance, grew in popularity in 2020. Δ8-THC is readily available in most gas stations or head shops and may be considered harmless by patients. However, an increasing number of patients admitted for psychiatric hospitalization report use, with limited literature on the effects.Case presentationsThis case report describes three individual cases of patients who required admission to a university psychiatric hospital after the regular use solely of Δ8-THC. All three patients developed psychotic and paranoid symptoms concurrently with the use of Δ8-THC, with a severity exceeding their previous historical presentations. The presenting psychotic symptoms were also atypical for all three patients. New-onset violence and visual hallucinations were noted in two of the patients, one patient with no previous psychiatric history and one patient while on a therapeutic dose of his antipsychotic. In the third case, a new onset of bizarre, fixed delusions of puppies dissolving in the bathtub developed.ConclusionThis report adds to the limited body of evidence on Δ8-THC documenting a temporal association between Δ8-THC use and the development of psychotic symptoms. A strong body of research already correlates the continued use of Δ9-THC with psychosis, and Δ8-THC acts at the same CB1 and CB2 receptors as Δ9-THC. Therefore, it is hypothesized that Δ8-THC may have similar adverse psychiatric effects as Δ9-THC. These conclusions are not without speculation, due to the need for self or collateral-reporting of Δ8-THC use as urine drug screening cannot distinguish Δ8-THC from Δ9-THC, and the patients' symptoms could be explained by medication non-adherence and primary psychotic disorders. However, physicians should be encouraged to gather a specific history of Δ8-THC use and treat patients with Δ8-THC-related intoxication and symptoms.

Delta-8-tetrahydrocannabinol Associated Manic Switch: A Case Report

“…2,3 There have been earlier reports of psychotic symptoms secondary to the use of D 8 -THC. 5,6 The similarities between D 8 -THC and D 9 -THC have been implicated behind the psychotomimetic effects of the former. 6 Various D 8 -THC compounds are being increasing marketed on many online platforms without adequate regulation.…”

“… 2 , 3 There have been earlier reports of psychotic symptoms secondary to the use of Δ 8 -THC. 5 , 6 The similarities between Δ 8 -THC and Δ 9 -THC have been implicated behind the psychotomimetic effects of the former. 6 …”

“… 5 , 6 The similarities between Δ 8 -THC and Δ 9 -THC have been implicated behind the psychotomimetic effects of the former. 6 …”

Use of Erythromycin in Clozapine Induced Constipation: A Case Report

“…2,3 There have been earlier reports of psychotic symptoms secondary to the use of D 8 -THC. 5,6 The similarities between D 8 -THC and D 9 -THC have been implicated behind the psychotomimetic effects of the former. 6 Various D 8 -THC compounds are being increasing marketed on many online platforms without adequate regulation.…”

“…5,6 The similarities between D 8 -THC and D 9 -THC have been implicated behind the psychotomimetic effects of the former. 6 Various D 8 -THC compounds are being increasing marketed on many online platforms without adequate regulation. A wide range of D 8 -THC products (gummies, tinctures, oil, vaporizing pens) are available for use with no adequate caution or awareness.…”